Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Clinical Trials

Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization

Phase 4

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Colchicine
Drug: Clopidogrel

First Posted Date: 2023-10-26

Last Posted Date: 2023-11-07

Lead Sponsor: Mikhail Zykov

Target Recruit Count: 200

Registration Number: NCT06102720

Locations: 🇷🇺
Sochi City Hospital #4, Sochi, Krasnodar Refion, Russian Federation
🇷🇺
Research Institute for Complex Issues of Cardiovascular Diseas, Kemerovo, Kemerovo Region, Russian Federation

Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

Phase 4

Not yet recruiting

Conditions: Coronary Heart Disease

Interventions: Drug: Ticagrelor
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2023-10-18

Last Posted Date: 2023-10-18

Lead Sponsor: Fu Wai Hospital, Beijing, China

Target Recruit Count: 292

Registration Number: NCT06088433

Locations: 🇨🇳
Fuwai Hospital, Beijing, Beijing, China

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

Phase 3

Recruiting

Conditions: Branch Atheromatous Disease

Interventions: Drug: Aspirin tablet
Drug: Tirofiban
Drug: Clopidogrel tablet

First Posted Date: 2023-09-14

Last Posted Date: 2025-04-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 516

Registration Number: NCT06037889

Locations: 🇨🇳
Chengde Central Hospital, Chengde, Hebei, China
🇨🇳
Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Hospital of Tsinghua University, Beijing, Beijing, China

and more 23 locations

Clopidogrel for the Prevention of Exacerbations in Severe COPD

Phase 3

Recruiting

Conditions: COPD
COPD Exacerbation Acute

Interventions: Drug: Clopidogrel Bisulfate 75Mg Tab

First Posted Date: 2023-09-01

Last Posted Date: 2023-10-03

Lead Sponsor: Lady Reading Hospital, Pakistan

Target Recruit Count: 162

Registration Number: NCT06021990

Locations: 🇵🇰
Saidu Teaching Hospital, Swat, Swāt, Khyber Pakhtunkhwa, Pakistan
🇵🇰
Pulmonology Department, Lady Reading Hospital, Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan

Low-dose NOAC Versus GDMT After LAAO

Not Applicable

Recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban 15mg
Drug: Aspirin 100mg
Drug: Rivaroxaban 10mg
Drug: Rivaroxaban 2.5mg
Drug: Clopidogrel 75mg

First Posted Date: 2023-07-27

Last Posted Date: 2023-07-27

Lead Sponsor: Xijing Hospital

Target Recruit Count: 4220

Registration Number: NCT05960721

Locations: 🇨🇳
Ling Tao, Xi'an, Shannxi, China

Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients

Not Applicable

Recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Clopidogrel monotherapy
Drug: Tailored anti-platelet therapy

First Posted Date: 2023-07-10

Last Posted Date: 2023-08-30

Lead Sponsor: Yonsei University

Target Recruit Count: 3434

Registration Number: NCT05936606

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Clopidogrel film-coated tablet 75 mg
Drug: Plavix® film-coated tablet 75 mg

First Posted Date: 2023-07-07

Last Posted Date: 2023-11-30

Lead Sponsor: Pharmtechnology LLC

Target Recruit Count: 60

Registration Number: NCT05934799

Locations: 🇷🇺
State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2", Yaroslavl, Yaroslavl Region, Russian Federation